25 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
2 Aug 23
Report of Foreign Private Issuer
8:05am
during the peak of the COVID-19 pandemic. 19 out of the 21 treated patients had mild-to-severe ARDS with their COVID-19. The Phase I/II clinical
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
22 Nov 21
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
8:00am
in an effort to further expand the trial in Europe as part of its regulatory strategy. Due to the impact of COVID-19 pandemic on trial enrollment to-date … :
Enlivex believes that COVID-19 will transition from a pandemic to an endemic, with multiple variants continuing to circulate throughout
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
clinical development programs may be extended due to direct and indirect impacts of the COVID-19 pandemic or new variants of the virus. For example … sepsis due to a lower number of pneumonic septic patients, as a result of the COVID-19 pandemic environment. The Company previously reported
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
to direct and indirect impacts of the COVID-19 pandemic or new variants of the virus. For example, there has been a delay in recruiting patients … patients, as a result of the COVID-19 pandemic environment. The Company previously reported that the Company expected to obtain interim results from
6-K
EX-99.1
ayy73f14z3zxbdmlwikv
22 Sep 21
Report of Foreign Private Issuer
6:02am
6-K
EX-99.1
ltzlq0x 4187
16 Aug 21
Report of Foreign Private Issuer
6:12am
6-K
EX-99.1
1gjmtykr7zdi28
9 Aug 21
Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update
8:00am
6-K
EX-99.2
e5iq7
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
6-K
EX-99.1
rxzqcxmw5pro ao2o
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
6-K
EX-99.2
n29jrj5qp1f
28 May 21
Condensed Consolidated Financial Statements
4:33pm
6-K
EX-99.1
qmcdo0hvw 29e7t5
28 May 21
Condensed Consolidated Financial Statements
4:33pm
6-K
EX-99.1
wse 00ahmtga5o82
3 Feb 21
Current Report
7:55am
6-K
EX-99.1
00jn57wex
3 Dec 20
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
8:00am
6-K
EX-99.2
cuy r4b7s9yf
30 Oct 20
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
63tcg
30 Oct 20
Condensed Consolidated Financial Statements
4:30pm
6-K/A
EX-99.2
me03f8qz7ys1 wg7geh
13 Oct 20
Condensed Consolidated Financial Statements
9:16am
6-K/A
EX-99.1
hkeoqtg7hq7noox
13 Oct 20
Condensed Consolidated Financial Statements
9:16am
6-K
EX-99.1
lufjy6tpw2ui5m
1 Oct 20
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
6:06am